GAD-7 Anxiety Screening Tool

About

The Generalized Anxiety Disorder-7 (GAD-7) is a self-administered screening and severity assessment tool for generalized anxiety disorder, developed by Dr. Robert L. Spitzer and colleagues in 2006. The GAD-7 was derived from the full Patient Health Questionnaire (PHQ) and validated specifically for identifying probable cases of generalized anxiety disorder (GAD) and assessing symptom severity. The GAD-7 asks patients to rate how often they have been bothered by specific anxiety-related problems over the past two weeks, with responses ranging from "not at all" (0) to "nearly every day" (3). Total scores range from 0 to 21, with higher scores indicating greater anxiety severity. The GAD-7 has been validated across multiple populations and clinical settings, demonstrating strong psychometric properties including good internal consistency (Cronbach's alpha = 0.92), test-retest reliability (intraclass correlation = 0.83), and convergent validity with other anxiety measures. At the standard cutoff of 10, the GAD-7 shows sensitivity of 89% and specificity of 82% for generalized anxiety disorder. The GAD-7 also has good sensitivity for detecting panic disorder (sensitivity 74%), social anxiety disorder (sensitivity 72%), and post-traumatic stress disorder (sensitivity 66%). The GAD-7 is recommended by the National Institute for Health and Care Excellence (NICE) for the identification and monitoring of GAD in adults. It is also widely used in primary care settings as a brief anxiety screening instrument that can be completed in under 5 minutes.

Formula

GAD-7 Total Score = Sum of all 7 item scores (0-3 each)

The GAD-7 total score is the sum of responses to all 7 questions. Each question is scored 0 ("not at all"), 1 ("several days"), 2 ("more than half the days"), or 3 ("nearly every day"). The minimum total score is 0 and the maximum is 21. A score of 10 or higher is considered the standard cutoff for a positive screen for generalized anxiety disorder. Scores of 5, 10, and 15 represent cut points for mild, moderate, and severe anxiety respectively.

Score Interpretation

The GAD-7 is a widely validated and clinically useful instrument for anxiety screening and severity assessment. Anxiety disorders are among the most prevalent mental health conditions worldwide, affecting approximately 301 million people according to the WHO. The GAD-7 addresses a critical gap in primary care, where anxiety disorders are often underdiagnosed and undertreated. The tool's brevity (7 items, under 5 minutes) makes it practical for busy clinical settings. The GAD-7 demonstrates good sensitivity across multiple anxiety disorders beyond GAD, including panic disorder (74%), social anxiety disorder (72%), and PTSD (66%). This transdiagnostic utility enhances its clinical value as a broad anxiety screening tool. The GAD-7 also correlates well with functional impairment and quality of life measures, and serial assessments can track treatment response over time. NICE guidelines recommend the GAD-7 for identification and monitoring of GAD, and the tool is embedded in the Improving Access to Psychological Therapies (IAPT) programme in the UK. The GAD-7 is available in over 50 languages and has been validated in diverse populations including elderly patients, pregnant women, and patients with comorbid medical conditions.

Reference Ranges